Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E18.75 EPS (ttm)2.67 Insider Own0.16% Shs Outstand1.63B Perf Week4.44%
Market Cap81.80B Forward P/E12.10 EPS next Y4.14 Insider Trans0.00% Shs Float1.63B Perf Month-2.79%
Income4.38B PEG1.70 EPS next Q0.85 Inst Own74.90% Short Float0.78% Perf Quarter-14.91%
Sales22.04B P/S3.71 EPS this Y-10.90% Inst Trans0.21% Short Ratio0.97 Perf Half Y-11.35%
Book/sh8.36 P/B6.00 EPS next Y6.92% ROA4.30% Target Price58.42 Perf Year-18.94%
Cash/sh4.19 P/C11.98 EPS next 5Y11.06% ROE11.30% 52W Range44.30 - 70.05 Perf YTD-3.58%
Dividend1.64 P/FCF73.43 EPS past 5Y15.30% ROI20.20% 52W High-28.45% Beta0.89
Dividend %3.27% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.80% 52W Low13.14% ATR1.69
Employees23700 Current Ratio1.50 Sales Q/Q8.30% Oper. Margin24.40% RSI (14)50.79 Volatility2.72% 3.27%
OptionableYes Debt/Eq0.54 EPS Q/Q128.60% Profit Margin6.50% Rel Volume1.56 Prev Close49.60
ShortableYes LT Debt/Eq0.42 EarningsJan 24 BMO Payout180.60% Avg Volume13.09M Price50.12
Recom2.30 SMA202.02% SMA50-2.23% SMA200-9.17% Volume20,400,075 Change1.05%
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Jan-19-19 08:03AM  3 Potential New Drugs Held Up by the Shutdown Motley Fool
06:00AM  Morningstar Runs the Numbers: Bogle Edition Morningstar
Jan-18-19 06:10PM  Cramer's game plan: This week, forecasts are more important than earnings CNBC
02:59PM  Should You Load Up on JNJ Stock Before Earnings? InvestorPlace
09:11AM  Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY Zacks
07:00AM  Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup American City Business Journals
Jan-17-19 06:57PM  Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA Zacks
04:34PM  1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet) Motley Fool
03:36PM  The Stable Value Stock Is Built to Weather Market Storms
12:38PM  What Kind Of Investor Owns Most Of Bristol-Myers Squibb Company (NYSE:BMY)? Simply Wall St.
11:31AM  Ligand (LGND) Takes a Hit on Citron's Negative Research Report Zacks
10:30AM  Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth Zacks
10:00AM  Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018 Motley Fool
07:20AM  The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab Zacks
06:55AM  Citron Says Ligand Has 80% Downside in Explosive Note Investopedia
Jan-16-19 07:15PM  Dealmaking surge confirms the stock market got far too ch... CNBC Videos
04:18PM  Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It Investor's Business Daily
12:51PM  Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming Investor's Business Daily
11:16AM  Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers Zacks
Jan-15-19 05:08PM  Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals
04:19PM  Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter Investor's Business Daily
09:40AM  Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer Zacks
09:32AM  How an East Bay cancer fighter once kicked to the curb by Big Pharma picked up its 4th drug approval American City Business Journals
08:49AM  Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer Zacks
Jan-14-19 06:05PM  5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019 Zacks
05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know Zacks
04:15PM  European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire
11:57AM  The Gold Rush of 2019
Jan-13-19 03:11PM  Barron's Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More Benzinga
09:00AM  3 Top Dividend Stocks Selling at a Discount Right Now Motley Fool
Jan-12-19 06:00PM  3 Top Biotech Stocks to Buy in January Motley Fool
06:00AM  Morningstar Runs the Numbers Morningstar
Jan-11-19 08:00PM  Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors
04:06PM  Lilly eyes more cancer deals, but wary of CAR-T, gene therapy Reuters
03:06PM  7 Pharmaceutical Stocks That Just Raised Prices This Year InvestorPlace
10:31AM  Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference CNBC
09:59AM  The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock InvestorPlace
09:56AM  Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer Zacks
09:54AM  Healthcare deals raise pulse of US lending in 2019 Reuters
09:04AM  3 Biotech Stocks Bubbling Away Investopedia
06:22AM  4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 Zacks
Jan-10-19 05:22PM  Ex-Juno executives reportedly seeking up to $1 billion for new Seattle startup American City Business Journals
04:13PM  Will Pfizer Join The Buying Spree With This Small Biotech Stock? Investor's Business Daily
03:23PM  3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year Motley Fool
09:56AM  Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting Zacks
Jan-09-19 07:32PM  [$$] Big Pharmas Cancer Race The Wall Street Journal
07:21PM  [$$] Big Pharma's Cancer Race The Wall Street Journal
08:51AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo Zacks
06:36AM  3 Reasons Buying Celgene Right Now Makes Sense Motley Fool
Jan-08-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
02:41PM  The 10 Best Health-Care Stocks to Buy for 2019 Kiplinger
02:11PM  Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer? InvestorPlace
11:15AM  CELGENE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG PR Newswire
09:58AM  Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo Zacks
09:52AM  Crowded Cancer Space Triggers Big M&A Deals: More in Store? Zacks
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
07:00AM  Debt Buybacks Could Be The New Stock Buybacks
07:00AM  BMS/ Celgene Deal Could Spark M/A Activity ACCESSWIRE
Jan-07-19 10:00PM  3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't Motley Fool
07:01PM  Jim Cramer: These Pharma Deals Are Game Changers
04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
03:36PM  Soon-Shiongs NantCell gets $30 million from Celgene American City Business Journals
03:18PM  Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019
03:17PM  5 Must-See Stock Charts for Tuesday, Including Roku InvestorPlace
03:04PM  5 Top-Selling Drugs With Growth Potential In 2019 Benzinga
09:59AM  Big Pharma Isn't Boring Any More as Cancer Deals Herald More M&A Bloomberg
09:42AM  Bristol-Myers and Celgene CEOs talk acquisition deal CNBC Videos
07:59AM  Celgene provides 2019 profit and sales outlooks above expectations MarketWatch
07:02AM  5 Things to Watch for at the JPMorgan Healthcare Conference Investopedia
04:00AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie Zacks
03:30AM  Tough Days for Giants Apple, Bristol-Myers Motley Fool
12:15AM  Should Investors Like Bristol-Myers' Buyout of Celgene? Motley Fool
Jan-06-19 06:15PM  Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene Motley Fool
10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
09:16AM  The Week Ahead In Biotech: Conferences, Clinical Trials Benzinga
Jan-05-19 11:07AM  Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-19 07:27PM  [$$] The Muscle Morgan Stanley Flexed in the $74 Billion Bristol-Myers Deal The Wall Street Journal
06:09PM  AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech Zacks
05:32PM  Johns Hopkins, Bristol-Myers must face $1 bln syphilis infections suit Reuters
04:24PM  Bristol To Become Top 5 Pharma And Other Fallout From Celgene Takeover Investor's Business Daily
04:06PM  Stock Market Rally Extends On Fed Chairman Powell, Jobs; Apple, Tesla, Delta Disappoint; Bristol-Myers Buys Celgene: Weekly Review Investor's Business Daily
02:33PM  Candel Therapeutics Completes $28.7 Million Series B Financing GlobeNewswire
01:31PM  Manufacturing, Apple, & Jobs: This Week's Top Market Stories Zacks
12:15PM  Johns Hopkins, Bristol-Myers must face $1 bln syphilis infections lawsuit Reuters
11:32AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders GlobeNewswire
10:24AM  Flex Pharma Finds A Lifeline In Merger With Oncology Biotech Salarius Pharma Benzinga
10:13AM  Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout InvestorPlace
10:07AM  Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks
10:02AM  Trump's FDA may greenlight drug-prescribing apps: Report Fox Business Videos
10:01AM  Company News For Jan 4, 2019 Zacks
10:01AM  Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus Zacks
09:39AM  Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal Reuters
09:36AM  Bristol-Myers to Acquire Leading Biotech Celgene for $74B Zacks
09:26AM  Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal Reuters
08:07AM  Should Celgene Investors Take Bristol's Money and Run? Motley Fool
08:01AM  Heres What Bristol-Myers Squibb Will Look Like After Acquiring Celgene Motley Fool
07:00AM  [$$] The Muscle Morgan Stanley Flexed in the $74 Billion Bristol-Myers Deal The Wall Street Journal
06:50AM  Today's Research Reports on Trending Tickers: Pfizer and Bristol-Myers Squibb ACCESSWIRE
12:22AM  PRESS DIGEST -Wall Street Journal - Jan 4 Reuters
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; Mirati Therapeutics, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM